{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T13:11:54Z","timestamp":1774530714543,"version":"3.50.1"},"reference-count":49,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T00:00:00Z","timestamp":1665100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Medical University of Lodz, Poland","award":["503\/1-093-01\/503-11-004"],"award-info":[{"award-number":["503\/1-093-01\/503-11-004"]}]},{"name":"Medical University of Lodz, Poland","award":["503\/1093-1\/503-11-003"],"award-info":[{"award-number":["503\/1093-1\/503-11-003"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Lenalidomide-based regimens are effective treatment options for patients with relapsed\/refractory multiple myeloma (RRMM). However, they are associated with an increased risk of infectious complications. This study examines the clinical factors influencing the occurrence of infection in MM patients treated with lenalidomide and dexamethasone (Rd). A retrospective analysis of all patients who received the Rd regimen between 2017 and 2021 at our institution was performed. The study group consisted of 174 patients and the median age was 65 years. Most patients (n = 110, 63.2%) received the Rd treatment in second-line treatment. The majority of patients (64.3%) received bortezomib-based regimens in the first line of treatment. The median progression-free survival was 12.6 (95% CI: 9.5\u201316.2) months, and the median overall survival was 22.3 (95% CI: 15.9\u201328.6) months. The overall response rate was 64.1%, 12.7% of patients achieved complete response, and 20.4% had a very good partial response. In multivariate logistic regression analysis, hypoalbuminemia (OR 4.2, 95% CI: 1.6\u201311.2, p = 0.0039), autologous hematopoietic stem cell transplantation (AHSCT) before Rd (OR 2.6, 95% CI: 1.0\u20136.7, p = 0.048), and anemia grade \u22653 (OR 5.0, 95% CI: 1.8\u201314.0, p = 0.002) were independent factors related to the occurrence of infections. In conclusion, in this large cohort of RRMM patients, AHSCT before Rd regimen therapy, hypoalbuminemia, and anemia during treatment were identified as three independent factors influencing the frequency of infections during Rd therapy. Patients with established risk factors may benefit from optimal supportive therapy.<\/jats:p>","DOI":"10.3390\/jcm11195908","type":"journal-article","created":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T23:39:31Z","timestamp":1665272371000},"page":"5908","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Risk Factors of Infection in Relapsed\/Refractory Multiple Myeloma Patients Treated with Lenalidomide and Dexamethasone (Rd) Regimen: Real-Life Results of a Large Single-Center Study"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2806-2583","authenticated-orcid":false,"given":"Damian","family":"Mikulski","sequence":"first","affiliation":[{"name":"Department of Hematooncology, Copernicus Memorial Hospital, Comprehensive Cancer Center and Traumatology, 93-510 Lodz, Poland"},{"name":"Department of Biostatistics and Translational Medicine, Medical University of Lodz, 90-419 Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6078-5415","authenticated-orcid":false,"given":"Pawe\u0142","family":"Robak","sequence":"additional","affiliation":[{"name":"Department of Hematooncology, Copernicus Memorial Hospital, Comprehensive Cancer Center and Traumatology, 93-510 Lodz, Poland"},{"name":"Department of Experimental Hematology, Medical University of Lodz, 90-419 Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wiktoria","family":"Ry\u017cewska","sequence":"additional","affiliation":[{"name":"Department of Hematology, Medical University of Lodz, 90-419 Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamila","family":"Sta\u0144czak","sequence":"additional","affiliation":[{"name":"Department of Hematology, Medical University of Lodz, 90-419 Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2879-7985","authenticated-orcid":false,"given":"Kacper","family":"Ko\u015bcielny","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Translational Medicine, Medical University of Lodz, 90-419 Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"G\u00f3ra-Tybor","sequence":"additional","affiliation":[{"name":"Department of Hematooncology, Copernicus Memorial Hospital, Comprehensive Cancer Center and Traumatology, 93-510 Lodz, Poland"},{"name":"Department of Hematology, Medical University of Lodz, 90-419 Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3411-6357","authenticated-orcid":false,"given":"Tadeusz","family":"Robak","sequence":"additional","affiliation":[{"name":"Department of Hematology, Medical University of Lodz, 90-419 Lodz, Poland"},{"name":"Department of General Hematology, Copernicus Memorial Hospital, 93-510 Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple Myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"Pawlyn","year":"2021","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1002\/ijc.33762","article-title":"Epidemiology, genetics and treatment of multiple myeloma and precursor diseases","volume":"149","author":"Hemminki","year":"2021","journal-title":"Int. J. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Padala, S.A., Barsouk, A., Barsouk, A., Rawla, P., Vakiti, A., Kolhe, R., Kota, V., and Ajebo, G.H. (2021). Epidemiology, Staging, and Management of Multiple Myeloma. Med. Sci., 9.","DOI":"10.3390\/medsci9010003"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/9789811404382119080004","article-title":"Novel Drugs for Multiple Myeloma","volume":"Volume 8","author":"Zaman","year":"2019","journal-title":"Topics in Anti-Cancer Research"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/leu.2012.119","article-title":"Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide","volume":"26","author":"Mendy","year":"2012","journal-title":"Leukemia"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.12708","article-title":"Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors I karos and A iolos via modulation of the E 3 ubiquitin ligase complex CRL4CRBN","volume":"164","author":"Gandhi","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells","volume":"343","author":"Udeshi","year":"2014","journal-title":"Science"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2014.107714","article-title":"Multiple myeloma and infections: A population-based study on 9253 multiple myeloma patients","volume":"100","author":"Blimark","year":"2015","journal-title":"Haematologica"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Balmaceda, N., Aziz, M., Chandrasekar, V.T., McClune, B., Kambhampati, S., Shune, L., Abdallah, A.-O., Anwer, F., Majeed, A., and Qazilbash, M. (2021). Infection risks in multiple myeloma: A systematic review and meta-analysis of randomized trials from 2015 to 2019. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08451-x"},{"key":"ref_14","unstructured":"Al-Anazi, K.A.A.-A.E.-K.A. (2018). Infections in Patients with Multiple Myeloma in the Era of Novel Agents and Stem Cell Therapies. Update on Multiple Myeloma, IntechOpen."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2016.07.025","article-title":"Infection risk with immunomodulatory and proteasome inhibitor\u2013based therapies across treatment phases for multiple myeloma: A systematic review and meta-analysis","volume":"67","author":"Teh","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12325-010-0104-8","article-title":"Management of the adverse effects of lenalidomide in multiple myeloma","volume":"28","year":"2011","journal-title":"Adv. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1007\/s00277-020-04023-4","article-title":"The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma","volume":"99","author":"Merz","year":"2020","journal-title":"Ann. Hematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: An open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/leu.2009.147","article-title":"Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"23","author":"Dimopoulos","year":"2009","journal-title":"Leukemia"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e418","DOI":"10.1200\/EDBK_159009","article-title":"Updated Diagnostic Criteria and Staging System for Multiple Myeloma","volume":"35","author":"Rajkumar","year":"2016","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: A consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2478\/ahp-2018-0016","article-title":"Vaccination of adult patients with hematological malignancies and patients with asplenia\u2014Guidelines of PTHiT and Infectious Diseases Working Group PALG","volume":"49","author":"Hus","year":"2018","journal-title":"Acta Haematol. Pol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/bmt.2009.263","article-title":"Vaccination of hematopoietic cell transplant recipients","volume":"44","author":"Ljungman","year":"2009","journal-title":"Bone Marrow Transpl."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41375-020-01016-0","article-title":"Recommendations for vaccination in multiple myeloma: A consensus of the European Myeloma Network","volume":"35","author":"Ludwig","year":"2021","journal-title":"Leukemia"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1080\/10428190500472503","article-title":"Immune parameters in multiple myeloma patients: Influence of treatment and correlation with opportunistic infections","volume":"47","author":"Brandhorst","year":"2006","journal-title":"Leuk. Lymphoma"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/sj.bmt.1703228","article-title":"IMMUNE RECONSTITUTION-Humoral immunity to viral and bacterial antigens in lymphoma patients 4\u201310 years after high-dose therapy with ABMT. Serological responses to revaccinations according to EBMT","volume":"28","author":"Husebekk","year":"2001","journal-title":"Bone Marrow Transplant."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1002\/cam4.2253","article-title":"Response to pneumococcal vaccination in multiple myeloma","volume":"8","author":"Renaud","year":"2019","journal-title":"Cancer Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/jmv.24621","article-title":"Virus reactivations after autologous hematopoietic stem cell transplantation detected by multiplex PCR assay","volume":"89","author":"Inazawa","year":"2016","journal-title":"J. Med. Virol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.3816\/CLM.2003.s.005","article-title":"The Implications of Anemia in Multiple Myeloma","volume":"4","author":"Mittelman","year":"2003","journal-title":"Clin. Lymphoma"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Lin, C., Shen, H., Zhou, S., Liu, M., Xu, A., Huang, S., Shen, C., and Zhou, F. (2020). Assessment of infection in newly diagnosed multiple myeloma patients: Risk factors and main characteristics. BMC Infect. Dis., 20.","DOI":"10.1186\/s12879-020-05412-w"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1038\/s41375-018-0133-x","article-title":"A predictive model for risk of early grade \u2265 3 infection in patients with multiple myeloma not eligible for transplant: Analysis of the FIRST trial","volume":"32","author":"Dumontet","year":"2018","journal-title":"Leukemia"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1007\/s00277-018-3401-y","article-title":"Low frequency of CD3+ CD4+ CD161+ T cells correlates with the occurrence of infections in refractory\/relapsed multiple myeloma patients receiving lenalidomide plus low-dose dexamethasone treatment","volume":"97","author":"Lee","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1042\/BCJ20210263","article-title":"Lactate cross-talk in host\u2013pathogen interactions","volume":"478","author":"Llibre","year":"2021","journal-title":"Biochem. J."},{"key":"ref_35","first-page":"52","article-title":"Lactate Contribution to the Tumor Microenvironment: Mechanisms, Effects on Immune Cells and Therapeutic Relevance","volume":"7","year":"2016","journal-title":"Front. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/s41591-018-0205-5","article-title":"Late-stage tumors induce anemia and immunosuppressive extramedullary erythroid progenitor cells","volume":"24","author":"Zhao","year":"2018","journal-title":"Nat. Med."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Wiedermann, C. (2021). Hypoalbuminemia as Surrogate and Culprit of Infections. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094496"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International Staging System for Multiple Myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00277-009-0841-4","article-title":"Serum albumin level is a significant prognostic factor reflecting disease severity in symptomatic multiple myeloma","volume":"89","author":"Kim","year":"2010","journal-title":"Ann. Hematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41408-022-00652-2","article-title":"A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma","volume":"12","author":"Encinas","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1007\/s00277-020-04125-z","article-title":"Risk and impact of invasive fungal infections in patients with multiple myeloma","volume":"99","author":"Tsai","year":"2020","journal-title":"Ann. Hematol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","article-title":"Consensus guidelines and recommendations for infection prevention in multiple myeloma: A report from the International Myeloma Working Group","volume":"9","author":"Raje","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41408-021-00588-z","article-title":"Impact of COVID-19 in patients with multiple myeloma based on a global data network","volume":"11","author":"Alonso","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e934","DOI":"10.1016\/S2352-3026(21)00278-7","article-title":"COVID-19 vaccination in patients with multiple myeloma: A consensus of the European Myeloma Network","volume":"8","author":"Ludwig","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma","volume":"372","author":"Stewart","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41746-020-0277-8","article-title":"Translating evidence into practice: Eligibility criteria fail to eliminate clinically significant differences between real-world and study populations","volume":"3","author":"Averitt","year":"2020","journal-title":"NPJ Digit. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.leukres.2014.12.007","article-title":"\u201cReal world\u201d outcome of lenalidomide plus dexamethasone in the setting of recurrent and refractory multiple myeloma: Extended follow-up of a retrospective multicenter study by the \u201crete ematologica pugliese\u201d","volume":"39","author":"Mele","year":"2015","journal-title":"Leuk. Res."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/19\/5908\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:47:33Z","timestamp":1760143653000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/19\/5908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,7]]},"references-count":49,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["jcm11195908"],"URL":"https:\/\/doi.org\/10.3390\/jcm11195908","relation":{"has-preprint":[{"id-type":"doi","id":"10.20944\/preprints202209.0018.v1","asserted-by":"object"}]},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,7]]}}}